Data Sheet (Cat.No.T3189)



B7/CD28 interaction inhibitor 1

Chemical Properties

CAS No.: 635324-72-0

Formula: C21H13F4N5O

Molecular Weight: 427.35

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

| Description | B7/CD28 interaction inhibitor 1 (CTLA-4 inhibitor) is a potent CTLA-4 inhibitor. | | | |
|---------------|--|--|--|--|
| | 7.0 | | | |
| Targets(IC50) | Others | | | |
| | | | | |

Solubility Information

| Solubility | DMSO: 85 mg/mL (198.9 mM),Sonication is recommended. |
|------------|---|
| | (< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|-----------|-----------|
| 1 mM | 2.340 mL | 11.700 mL | 23.400 mL |
| 5 mM | 0.468 mL | 2.340 mL | 4.680 mL |
| 10 mM | 0.234 mL | 1.170 mL | 2.340 mL |
| 50 mM | 0.0468 mL | 0.234 mL | 0.468 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Zhao Y, Hao C, Li M, et al. PD-1/PD-L1 inhibitor ameliorates silica-induced pulmonary fibrosis by maintaining systemic immune homeostasis. Biomedicine & Pharmacotherapy. 2022, 148: 112768.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street, Wellesley Hills, MA 02481

Page 1 of 1 www.targetmol.com